|
|
| Line 1: |
Line 1: |
| ==Administration==
| | #REDIRECT[[Ribavirin]] |
| *Type: Antiviral- FDA approved for [[Hepatitis C]], severe [[RSV]] infection. Off-label use: [[herpes simplex]], [[influenza]], [[viral hemorrhagic fever]]
| |
| *Dosage Forms: 200 tab, 200 cap
| |
| *Routes of Administration: Oral, inhalation
| |
| *Common Trade Names: Copegus, Rebetol, Ribasphere
| |
| | |
| ==Adult Dosing==
| |
| *200-1000mg daily (dose depends on genotype and concurrent treatment with interferon)
| |
| | |
| ==Pediatric Dosing==
| |
| *Hep C: >2 years old: 15mg/kg daily OR 400-1200mg daily
| |
| *RSV (severe cases): 20mg/ml aerosolized over 12-18 hours x 3-7 days
| |
| | |
| ==Special Populations==
| |
| *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: X
| |
| *[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out
| |
| *Renal dosing: reduced doses for mild-moderate impairment, do not use if CrCl <50
| |
| | |
| ==Contraindications==
| |
| *Allergy to class/drug
| |
| *[[Autoimmune hepatitis]]
| |
| *Coadministration with didanosine
| |
| *Hemoglobinopathy (e.g. [[thalassemia]], [[sickle cell]])
| |
| *[[Pregnant]] or potentially pregnant women, men who may impregnate someone
| |
| *Renal impairment (CrCl <50)
| |
| | |
| ==Adverse Reactions==
| |
| ===Serious===
| |
| *[[Hemolytic anemia]], [[TTP]]
| |
| *[[Bacterial disease]]
| |
| *[[Hepatotoxicity]]
| |
| *[[MI]]
| |
| *[[Suicide]]
| |
| | |
| ===Common===
| |
| *[[Neutropenia]]
| |
| *[[Nausea]], [[vomiting]], [[diarrhea]]
| |
| *Asthenia, [[dizziness]], [[fatigue]]
| |
| *Weight loss
| |
| *[[Pruritus]]
| |
| | |
| ==Pharmacology==
| |
| *Half-life: ~300 hours
| |
| *Metabolism:
| |
| *Excretion: Mostly renal
| |
| | |
| ==Mechanism of Action==
| |
| *Mechanism not well understood
| |
| | |
| ==Comments==
| |
| | |
| ==See Also==
| |
| *[[Viral hepatitis]]
| |
| *[[Hepatitis C]]
| |
| | |
| ==References==
| |
| <references/>
| |
| [[Category:Pharmacology]]
| |
